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 20 
Practice Points  21 
• Clinical events during the natural history of chronic hepatitis B virus (HBV) are 22 
intricately linked to the host immune system, but the details of host-virus interactions 23 
remain insufficiently understood  24 
• HBV is sensed by the immune system, but the ensuing antiviral responses are not 25 
sufficient to prevent chronicity in most newborns and some adults 26 
 27 
Research Agenda  28 
• To understand the basic mechanisms of HBV clearance, persistence and long lasting 29 
HBV cure by using the most advanced and detailed biomedical techniques, down to 30 
the single cell level.  31 
• To gather more information on the intrahepatic, rather than the peripheral, immune 32 
populations, as their phenotype and function are very different  33 
• To focus on longitudinal assessment of immune parameters, thereby excluding 34 
effects of cohort variation in HBV research   35 
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Abstract  36 
Clinical events and the host immune response during hepatitis B virus (HBV) infection are 37 
intricately linked. Despite decades of research, important questions concerning the 38 
immunopathogenesis of chronic HBV infection remain unanswered. For example, it is 39 
unclear which immune parameters facilitate persistence, and if HBV can be completely 40 
cleared from the human liver. Recent technological breakthroughs now allow researchers to 41 
address these seemingly basic, but essential questions surrounding HBV immunity. It will be 42 
important to better define the molecular underpinnings of immune cell function and 43 
dysfunction during chronic disease and in controlled infection, with particular focus on the 44 
liver, as little information is available on the intrahepatic compartment. In the near future, it 45 
may be possible to solve some of the controversy surrounding the immune responses to 46 
HBV, and establish the features of both the innate and adaptive arms of the immune system 47 
required to achieve sustained control of HBV infection.   48 
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HBV and the immune response: The big questions 49 
The natural history of HBV infection is exceptionally complex, and, not surprisingly, so are 50 
the host immune responses. For almost every clinical or virological change during the course 51 
of HBV infection, there are proven or suspected correlates in host immunity, some of which 52 
might represent the underlying cause of the observed alterations in disease, while others will 53 
be consequences of the change, for example in viral load. Recent advances in experimental 54 
and analytical capabilities now allow researchers to address seemingly basic but still 55 
unsolved questions surrounding HBV immunity. We have formulated several questions 56 
regarding host-virus interactions whose answers we deem most relevant for a better 57 
understanding of HBV immunopathogenesis and for the development of novel therapeutic 58 
strategies (Figure 1). After addressing these issues, we will highlight some of the progress 59 
that has already been made in the field of chronic HBV.  60 
First is the question of what determines the different outcome in acute HBV infection, 61 
as the virus is spontaneously controlled in some subjects, while becoming chronic in others. 62 
Here we have to consider two completely distinct scenarios: adult HBV infection typically 63 
leads to HBV control, whereas natal infection results in chronicity in almost all cases, with 64 
declining but still very significant chronicity rates if infection occurs before the age of 5. 65 
However, not much is known of the immunological processes, resulting in these striking 66 
differences. We know much more about acute and chronic infection “after the fact”, i.e. in 67 
adult patients who have established chronic infection or successful HBV control. Studies 68 
during the early phase of infection, when the outcome is not yet determined, are much more 69 
difficult to undertake. The best opportunity for further insights will be studies in young 70 
children who present with early infection. Immunological studies in this population are 71 
feasible, but until recently had to be very limited in scope, in part because only small 72 
amounts of blood can be drawn for analysis. New technologies now enable analysis of low 73 
volume samples with high resolution and without the requirement of research facilities close 74 
to the clinic.  75 
Immune responses of chronically infected adults have been performed for decades, 76 
but, as we will describe in this review, often have conflicting results. These variations are 77 
partly caused by methodological differences, but the variation among patient characteristics 78 
also has significant impact [1]. In addition to establishing the range and variation of immune 79 
cell parameters during frequent subtypes of chronic infection, we also need to know if, and to 80 
what degree, antiviral therapy is able to reconstitute those parts of the HBV immune 81 
response previously insufficient for functional control. At least based on the different antibody 82 
patterns observed in treated patients, it seems obvious that restoration of immunity is not 83 
uniform, and certainly in most subjects not sufficient for viral control in the absence of 84 
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therapy. But what exactly is restored, whether immune restoration is just a consequence of 85 
diminished viral replication that is lost in the absence of antiviral treatment, or whether 86 
restored immunity is independent or even the cause of viral suppression, needs to be 87 
evaluated in much more detail. In this context it is also important to define whether circulating 88 
viral proteins, such as HBs antigen (HBsAg), are indeed the key immunosuppressive agents 89 
that in vitro studies have suggested[2].  90 
Another important question is what level of HBV control can actually be achieved 91 
through the host immune response. It is clear that even after HBsAg clearance from the 92 
blood, covalently closed circular DNA (cccDNA) can remain in hepatocytes indeterminately, 93 
evident from the well-documented cases of HBV reactivation in anti-HBsAg positive subjects 94 
undergoing immune-ablative therapies. Whether this is the dominant or even the only 95 
scenario in “resolved” HBV infection, or whether some patients are indeed able to completely 96 
clear HBV DNA based on an even more effective immune response, will require larger 97 
studies analyzing liver tissue for cccDNA in these populations.  98 
Finally, greater insights need to be generated into what actually happens in the liver 99 
as the site of infection, since both the composition of immune populations as well as their 100 
functional and phenotypic profiles are different from what is observed in the blood. New 101 
technologies now allow analysis of rare immune populations in the liver, down to cells on the 102 
single cell level. Similarly, we should utilize the improved tools for the integrative analysis of 103 
cellular processes and immune functions in order to understand the immune response to 104 
HBV more holistically. Many components of the immune response, both innate and adaptive, 105 
have to act in concert in different scenarios of viral control and viral persistence. Below we 106 
will broadly summarize the current knowledge of both innate and adaptive arms of the 107 
immune responses to HBV infection. While the studies described below do not yet provide 108 
definitive answers, they are the foundation for future investigations into the issues raised 109 
above. 110 
 111 
  112 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Innate immune responses to HBV 113 
HBV is transmitted upon contact with blood or body fluids of an infected person. A minute 114 
amount of HBV virions in the bloodstream is sufficient for infection of hepatocytes [3]. The 115 
HBV virion enters the hepatocyte via the sodium taurocholate co-transporting polypeptide 116 
(NTCP), a bile receptor located on the basolateral membrane, contributing to its specificity to 117 
human or chimpanzee hepatocytes [4]. After the envelope protein mediates fusion of the viral 118 
and endosomal membranes, the capsid enters the cytoplasm and the viral DNA is released 119 
into the nucleus through nuclear pores. Upon import into the nucleus, HBV can integrate into 120 
the host genome or be present as non-integrated covalently closed circular DNA (cccDNA). 121 
The cccDNA molecule will serve as a template for replication leading to infection of more 122 
hepatocytes, and can persist even after HBsAg loss [5]. As circulating blood passes the liver, 123 
HBV can easily spread to other hepatocytes.  124 
 125 
The detection of HBV by infected hepatocytes  126 
The sensing of HBV and triggering of intracellular antiviral mechanisms can occur on the cell 127 
membrane by Toll-like receptors (TLR), in the endosome by TLR7 or TLR9, and in the 128 
cytoplasm by sensors, such as intracellular retinoic acid inducible gene I (RIG-I) and 129 
melanoma differentiation gene 5 (MDA5) upon ligation with viral proteins or nucleic acids. 130 
Although some controversy exists, it has been reported that TLR2, MDA-5 and RIG-I are 131 
involved in sensing of HBV. For the cytoplasmic sensor RIG-I, it was demonstrated that HBV 132 
pre-genomic RNA triggered its activation, resulting in the release of interferon (IFN)-λ but not 133 
type-I IFN by HBV infected primary human hepatocytes and hepatoma cell lines[6]. Release 134 
of IFN by hepatocytes and possibly other cells induces expression of hundreds of IFN-135 
stimulated genes (ISGs) with potent antiviral activity. However, the HBV-induced IFN 136 
responses are weak [7, 8], which is reflected by the usual lack of clinical symptoms during 137 
the acute HBV infection. Also, early data from animal models showed that HBV does not 138 
induce the release of type-I IFN [9, 10]. The absence of symptoms and the modest IFN 139 
induction by HBV led to adaptation of the term ‘stealth virus’. However, IFN responses and 140 
ISG induction are present, albeit marginal compared to other chronic viruses [7, 8]. The use 141 
of cccDNA as a transcriptional template in the nucleus likely contributes to HBV’s capacity to 142 
limit detection in hepatocytes. Adding to this, viral proteins, like HBV polymerase and HBx 143 
protein, directly inhibit the cellular machinery that detects replication intermediates. It is 144 
currently unknown which pattern recognition receptor or signaling pathway is essential for 145 
early viral control in vivo, and perhaps more relevant to the majority of patients, to HBV 146 
persistence in humans.  147 
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As the human liver is the site of HBV replication and contains high viral protein 148 
concentrations, the most appropriate approach for addressing basic questions concerning 149 
HBV detection is to evaluate liver material. Unfortunately, such studies are rare. Lebosse et 150 
al. [11] analyzed RNA extracted from liver biopsies of chronic HBV patients and showed low 151 
intrahepatic IFNɑ expression relative to healthy controls, which was unaffected by viral 152 
replication. Previously, we analyzed liver biopsies from patients in specific clinical phases of 153 
chronic HBV. By comparing the transcriptome of liver and blood samples from patients in 154 
distinct clinical phases of HBV we found that, ISG are transcribed even in patients presumed 155 
to be ‘immune tolerant’ to HBV [12]. Transcription of catalytic polypeptide-like 3B, a protein 156 
related to cccDNA degradation [13], was increased in the immune tolerant phase, which 157 
suggests that the capacity to limit the establishment of high amounts of cccDNA may be 158 
different between phases, but not absent in any phase. These two studies using human liver 159 
tissue raise significant doubt about the labels ‘stealth virus’ and ‘immune tolerant’, as HBV is 160 
indeed sensed by the host immune system and antiviral responses are initiated, even as they 161 
are not sufficient to halt viral replication and spread in persons with chronic infection. 162 
Whether these differences of innate intrahepatic responses are caused by chronic HBV 163 
replication, or reflect immune characteristics that select patients for persistent infection, 164 
remains to be clarified using longitudinally acquired samples of human liver.  165 
 166 
The interaction of antigen presenting cells and HBV   167 
Intrahepatic leukocyte populations lining the sinusoidal lumen of the portal branches as well 168 
as hepatocytes are constantly in contact with huge amounts of bacterial antigen derived from 169 
the gut. Tolerance during exposure to high antigen loads is essential for host survival, and 170 
the relative tolerogenic milieu of the liver is well described[14]. Illustrative of the complex 171 
balance of the liver immune system is the fact that, despite its tolerant nature, HBV is cleared 172 
after transmission in the vast majority of infected individuals. For the development of 173 
treatment strategies, it is important to evaluate the leukocyte populations involved in this 174 
process. Liver residing antigen presenting cells, like Kupffer cells and dendritic cells (DC), 175 
could potentially modulate host immune responses to a phenotype enabling chronic viral 176 
infection, but limited information exists on the interaction between these cells and HBV 177 
(Figure 2). DC are crucial for their ability to efficiently present antigen to naïve CD4 T cells, or 178 
to CD8 T cells via cross-priming. At present, the impact of persistent HBV infection on the 179 
DC compartment is not fully clear. In vitro studies have demonstrated that the presence of 180 
viral antigen may limit DC functionality[15]. Both plasmacytoid and myeloid DC can present 181 
antigens to T cells, and can, depending on the cytokine milieu, skew T cell effector function 182 
towards tolerance or activation. Plasmacytoid DC are specialized in the production of high 183 
levels of type I and type III IFN, thereby potentially initiating innate immune responses to 184 
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HBV after recognition of viral nucleic acids via TLR7 or TLR9. However, based on ex vivo 185 
assays, DC function during chronic HBV patients may be hampered. The frequency of both 186 
myeloid DC and plasmacytoid DC is not changed in the majority of studies with patient 187 
material, but others have reported various functional differences compared to healthy 188 
controls [16-19]. Possibly via downregulation of TLR7 or TLR9, plasmacytoid DC seem to be 189 
less capable to produce IFNɑ, especially when DC are derived from patients with 190 
considerable liver inflammation [17, 20].  191 
Kupffer cells are liver resident macrophages, and make up 15-20 % of the 192 
intrahepatic leukocytes [21]. We have previously shown that Kupffer cells can interact with 193 
HBsAg in vivo, which led to increased pro-inflammatory cytokine production compared to 194 
healthy controls[22]. However, HBV proteins like HBeAg may interfere with Kupffer activation 195 
by downregulation of TLR expression as shown in vitro[23]. In line with this finding, patient-196 
derived peripheral monocytes were also found to have lower TLR2 expression compared to 197 
healthy controls[24]. Kupffer cells can play different roles in the presence of HBV antigens, 198 
as was illustrated in a rat model, where HBV causes Kupffer cells to produce more of the 199 
pro-fibrogenic and tolerogenic cytokine TGF-β1, as opposed to the pro-inflammatory 200 
cytokines IL-6, IL-1 and TNF[25]. To prevent continuous activation and excessive 201 
intrahepatic inflammation, Kupffer cells become refractory to subsequent endotoxin 202 
challenge, which may contribute to the tolerogenic liver environment. Furthermore, Kupffer 203 
cells can interact and influence other immune cells, either directly via cell-cell contact or 204 
indirectly via the activity of cytokines. Indirect activation of natural killer (NK) cells can take 205 
place via Kupffer cell-derived IL-12 and IL-18[22, 26]. 206 
 207 
NK cell function and phenotype in chronic HBV    208 
NK cells can recognize and lyse infected cells, and may therefore be an important effector 209 
cell that plays a role during persistence of HBV. Indeed, the frequency and function of NK 210 
cells in peripheral blood of chronic patients has been studied extensively, and it seems clear 211 
that the balance of NK cell stimulatory and inhibitory signals significantly impacts their 212 
activity, which in turn correlates with patient outcomes during the natural history of chronic 213 
HBV. One of the major effector functions of NK cells, the production of the antiviral and anti-214 
fibrotic cytokine IFNɣ, is reported to be unaffected during chronic HBV by some studies [27, 215 
28] but reduced in others[25, 29, 30]. IFNɣ release by NK cells mediates the non-cytolytic 216 
clearance of HBV by virus-specific CD8 T cells[31, 32]. Another beneficial effect may be that 217 
IFNɣ induces the production of the antiviral APOBEC proteins A3A and A3B directly affecting 218 
the integrity of cccDNA [33]. In a transgenic mouse model, the potential of IFNɣ was 219 
dramatically demonstrated by injection of the NKT cell activating agent alpha-220 
galactosylceramide, which stopped HBV from replicating, and led to infiltration of NK cells 221 
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into the liver[34]. In humans, however, alpha-galactosylceramide affected HBV DNA levels in 222 
only a subset of human chronic HBV patients, and the treatment was not well tolerated [35]. 223 
During chronic HBV infection, the cytotoxic capacity of NK cells seems to remain intact[36], 224 
which together with the impaired cytokine production as described by some studies, 225 
suggests the existence of a functional dichotomy of NK cells in chronic HBV. However, given 226 
the conflicting reports in the literature, it is obvious that more detailed and more controlled 227 
studies need to be performed. A recent study performed by our group compared NK cell 228 
phenotype and function in blood among HBV patients in different clinical phases. 229 
Interestingly, despite big differences in viral load and ALT levels between patients, the NK 230 
cell compartment demonstrated only subtle differences between the patients cohorts[37]. 231 
Concerning their activation, a combination of IL-12, IL-15 and IL-18 secreted by other 232 
intrahepatic immune cell populations, including activated Kupffer cells, seems to be the most 233 
likely mechanism. Direct contact with virally infected cells or HBV DNA in the blood may be a 234 
less effective stimulus for NK cells, based on work by Bonoroni et al., who describe no 235 
correlation between viral load and peripheral NK activation [38], which is in line with our 236 
previous study[37]. Also supporting this finding is the observation that tenofovir-induced viral 237 
load reduction did not significantly alter intrahepatic NK cell activation as demonstrated using 238 
the analysis of fine-needle aspirate liver biopsies, even after six years of viral 239 
suppression[39]. The capacity of intrahepatic NK cells to inhibit fibrogenesis through IFNɣ 240 
production [40], or by killing stellate cells that are driving collagen syntheses in the liver [41], 241 
may also be relevant for clinical outcomes. However, in contrast to the above described 242 
beneficial effects of NK cells, their activation may alternatively facilitate HBV persistence, as 243 
was recently illustrated by the finding that HBV-specific CD4 T cells expressing death ligands 244 
(not seen in healthy controls) can be targets for NK cell mediated killing [42]. In a similar 245 
fashion, NK cells have been shown to kill HBV-specific CD8 T cells. 246 
 247 
Adaptive immune responses during chronic HBV 248 
Adaptive immune responses by virus-specific CD4 and CD8 T cells, B cells and antibodies 249 
are indispensable for HBV control[43]. These responses develop relatively late in HBV 250 
infection compared to other viral infections: at ten to twelve weeks post exposure[44]. This 251 
late emergence of adaptive immunity is thought to be a consequence of the stealthy nature 252 
of early HBV infection, with low viral replication and minimal to no activation of innate 253 
immunity. This delayed response is not per se a factor in HBV chronicity, as it is also 254 
observed in the vast majority of adult patients who go on to control the virus spontaneously. 255 
While we have learned many important details about how adaptive immune responses 256 
emerge and evolve from the early phase of infection throughout viral resolution or chronic 257 
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viremia[43], much remains to be determined in order to fully appreciate the exact 258 
mechanisms driving successful and failing adaptive immune responses targeting HBV. This 259 
is especially true as our appreciation of the complexity and diversity of different players of the 260 
adaptive immune response, mostly defined in animal models, has grown faster than our 261 
ability to translate such integrative concepts into human infection[45]. 262 
 263 
Detection of HBV-specific CD4 T cells 264 
Virus-specific CD4 T lymphocytes are key regulators of both efficient B cell/antibody and 265 
CD8 T cell responses and thus are thought to be essential to the control of most viral 266 
infections [46]. Unfortunately, virus-specific CD4 T cells are also notoriously difficult to study, 267 
as they are rather low in frequency and complex in their phenotypes and function. Overall, 268 
our understanding of the HBV-specific CD4 response remains incomplete. The seminal 269 
chimpanzee studies defining the importance of CD4 T cells cells by analyzing the impact of 270 
CD4 T cell depletion on the course of infection are not straightforward in their findings, as 271 
depletion of CD4 T cells before infection leads to chronic HBV infection, while depletion just 272 
before the rise of viremia and liver enzymes did not alter the natural course of infection[46, 273 
47]. These findings support a critical role of CD4 T cells in the control of HBV infection, but 274 
also raise questions about the exact role of T cell help and its mode of action. Generally, 275 
HBV-specific CD4 T cells appear in the blood seven to ten weeks after infection, in parallel 276 
with the emergence of HBV-specific CD8 T cells and antibodies[44, 48]. The CD4 T cells 277 
mostly target epitopes in HBV core, though minor responses against surface, polymerase 278 
and x protein have also been described[49-52]. In patients with acute or controlled HBV 279 
infection, CD4 responses are more broadly directed and more vigorous, compared to 280 
patients with established chronic viremia. Functionally, HBV-specific CD4 T cells have been 281 
shown to predominantly secrete Th1 type cytokines[53], though overall studies assessing the 282 
phenotype and function of the cells directly ex vivo are very few and rather limited. In this 283 
context it is important to remember that most of these studies were performed in the era 284 
when standard proliferation and ELISpot assays where the only means to assessing virus-285 
specific CD4 T cell responses, and as we have learned from other infections such as with 286 
HCV, these functional assays might miss significant parts of the response[54]. In addition, 287 
HBV-specific CD4 T cells at the site of infection might be quite different than those analyzed 288 
in the blood. Indeed, after in vitro expansion from liver biopsies obtained in patients with 289 
chronic infection, intrahepatic CD4 T cells have shown a distinct functional profile compared 290 
to those derived from blood, with the secretion of IL-4 and IL-5 in addition to Th1 type 291 
cytokines[55]. A reassessment of HBV-specific CD4 T cell responses using current 292 
methodologies, i.e. HLA class II tetramers, for direct ex vivo phenotyping and flow based cell 293 
sorting, followed by omics analyses, seems imperative in order to obtain a more detailed 294 
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understanding of this central component of the adaptive immune response. These methods 295 
enable analysis of single cells, and thus might allow ex vivo studies even in infection at 296 
young age, for which we currently have no significant data about the CD4 T cell response. 297 
 298 
Detection of HBV-specific CD8 T cells 299 
In contrast to CD4 T cells, CD8 T cell responses have been studied much more widely and in 300 
greater detail, including direct ex vivo analyses[56]. They are essential for HBV control, as 301 
their depletion invariantly led to chronicity in chimpanzees[46]. HBV-specific CD8 T cells 302 
become readily detectable six to eight weeks after infection in adults, and their appearance 303 
coincides with a decrease in viral load that is observed even before the onset of liver 304 
injury[44], supporting the contribution of non-cytolytic elimination of intracellular virus to viral 305 
control. CD8 lymphocytes targeting all HBV proteins have been identified[43] and shown to 306 
have cytolytic as well as non-cytolytic effector functions[57]. Non-cytolytic effector functions 307 
could be especially relevant, as hepatocytes have been shown to be quite resilient to cell-308 
mediated killing in vitro[58]. While the exact immunological determinants of CD8 mediated 309 
HBV control are difficult to define with certainty in humans, the development of a sustained, 310 
broad and polyclonal CD8 T cell response that is highly functional is seen as conditio sine 311 
qua non for HBV control. To what degree such a CD8 response is dependent on other arms 312 
of the immune response, be it CD4 T cell help or a preceding innate response, is not fully 313 
clear.  314 
 315 
Importantly, there is also a good amount of literature on intrahepatic CD8 T cells targeting 316 
HBV, mostly from chronic infection. Detection of HBV-specific CD8 T cells by tetramer 317 
staining of cultured intrahepatic lymphocytes revealed that the frequencies of virus specific 318 
CD8 T cells were inversely correlated with the degree of liver injury[59], supporting the 319 
hypothesis that specific responses might be not only important for disease resolution, but 320 
also for protection from progressive liver disease. Another pioneering study using fine needle 321 
aspirate biopsies to analyze intrahepatic lymphocytes during acute infection provided 322 
longitudinal characterization of HBV-specific CD8 T cells directly ex vivo without in vivo 323 
expansion. HBV-specific CD8 T cells were highly enriched in the liver during the acute phase 324 
of infection and remained detectable after HBsAg seroconversion and full clinical 325 
recovery[60]. A similar approach was also employed in chronically infected patients; 326 
revealing that virus specific CD8 T cells were most readily detected during the inactive carrier 327 
phase[61]. Altogether, current evidence illustrates differences in phenotype and function 328 
between peripheral and intrahepatic lymphocytes, and during different stages of HBV 329 
infection. Since one can now analyze cells from liver biopsies or fine needle aspirates with 330 
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much more powerful analytic tools, this opportunity should be used to deepen our 331 
understanding of the CD8 T cell response in acute and chronic infection, and during therapy. 332 
 333 
Chronic HBV and functional T cell impairment 334 
Once patients are chronically infected, especially in those patients exposed in early 335 
childhood, there is usually an extended phase that has been described as immune tolerant, 336 
with high levels of viremia but no or very little liver disease. It has been postulated that during 337 
this phase T cell responses are mostly absent and/or non-functional. Recent data indicate 338 
that this is not the case, and instead T cells are readily detectable in these patients and 339 
seem, if anything, more and not less functional than those in later, so called immune active, 340 
stages of disease[12]. This “immune tolerant” phase of HBV might hold more surprises and 341 
certainly warrants further investigation. During later stages of chronic infection, the repertoire 342 
of detectable HBV-specific T cells is limited and their frequencies are rather low, at least in 343 
the blood, and especially so in patients with high viral loads[62]. Preserved HBV-specific 344 
CD8 T cells become gradually more functionally impaired, or exhausted, which is thought to 345 
be driven by persistent antigen exposure. CD8 T cell exhaustion in chronic HBV infection 346 
mirrors that described in other chronic viral infections in mice and humans, with the sustained 347 
expression of inhibitory receptors, such as PD-1, TIM-3 and 2B4, reduced proliferative 348 
capacity and poor effector functions such as reduced IFNɣ and IL-2 secretion [63-65]. The 349 
exhausted state is also associated with distinct expression patterns of transcription factors, 350 
compared to functional effector or memory T cells, most notably low expression of T-bet[66] 351 
The cells seem also increasingly susceptible to apoptosis through upregulation of Bim and 352 
TRAIL-R2[67, 68], two key regulators of cell death. Whether the functional exhaustion of 353 
HBV-specific CD8 T cells is the sole or dominant contributor to CD8 T cell failure, or whether 354 
the virus can also escape through the generation of viral escape sequence variants, like in 355 
HIV and HCV infection, is currently an open question. HBV as a DNA virus is much more 356 
genetically stable compared to HIV and HCV, and early studies supported the idea that HBV 357 
displayed little variability that could be linked to immune pressure[69]. However, a recent 358 
study revealed viral variation compatible with escape mutations in both the core and 359 
envelope sequence and to a lesser extent in the polymerase sequence of HBV[70, 71]. 360 
Future studies in this area should further define the mechanisms of T cell exhaustion and 361 
whether exhausted T cells in chronic HBV infection could potentially be reinvigorated through 362 
immunotherapeutic interventions. In addition, we need to define the contribution of viral 363 
variants to the failure of HBV adaptive immunity. 364 
 365 
Functional T-cell restoration under treatment 366 
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If T cell exhaustion is principally maintained by persistent antigen exposure, long-term 367 
therapy with successful control of viremia, should, to some degree, be capable of restoring T 368 
cell function. This would be especially relevant for immunotherapeutic approaches that most 369 
likely will be applied in the context of antiviral therapy. This has been studied in some detail, 370 
though the complexity of antiviral treatments, but also of the course of chronic HBV infection 371 
itself, makes interpretation of the data challenging [72-75]. Boni et al compared nucleos(t)ide 372 
treated chronic HBV infected patients to those with untreated or resolved infection. PBMC 373 
were analyzed either directly ex vivo with class I dextramers or for their proliferative capacity 374 
and cytokine production after in vitro expansion. Ex vivo analysis of virus-specific T cells 375 
suggested continued impairment even after long-term treatment, though after in vitro 376 
expansion some functional properties were partially restored, indicating some improvement 377 
of the T cell populations[73]. A similar study design has also been performed in IFNɑ treated 378 
chronic HBV patients and failed to detect improved T cell function, at least in terms of 379 
cytokine production[74]. Whether the modest T cell recovery is due to the remaining high 380 
levels of HBsAg in serum, despite the control of viral replication, is an important and 381 
controversial question. While it is widely assumed that surface antigen has a directly 382 
negative effect on T cell function, this hypothesis is mostly based on in vitro studies using 383 
high doses of recombinant proteins. One wonders how this effect mediated by circulating 384 
proteins could be specific to HBV-specific immune cells as there is no experimental evidence 385 
that adaptive immune responses to other pathogens are similarly impaired as those targeting 386 
HBV. Clinically chronic HBV patients are also not showing signs of significant immune 387 
impairment. Further studies analyzing the impact of circulating HBV antigens on HBV 388 
immune responses in vivo are needed, together with a more detailed and comprehensive 389 
assessment of the integrated adaptive immune response in well-defined longitudinal cohorts 390 
undergoing structured antiviral treatment and treatment interruptions.  391 
 392 
Regulatory T cells 393 
Regulatory T (Treg) cells are T cells that can regulate the local immune response via cell-cell 394 
contact or via secretion of cytokines, such as TGF-β or IL-10. Treg cells play a central role in 395 
immunological tolerance to self- and foreign antigens by suppressing activation, proliferation 396 
and effector functions of a wide range of lymphocyte subsets[76]. The best-known are 397 
CD25+FoxP3+CD4 natural Treg cells that directly inhibit other T cells. In addition, an 398 
increasing number of other regulatory T cell types have been described, including CD8 T 399 
cells with inhibitory functions. Most studies in HBV have focused on natural CD4 Treg cells in 400 
the peripheral blood, where these cells usually constitute between 3 and 10% of the total 401 
CD4 T cell population. Confusingly, while some studies have found increased intrahepatic 402 
and peripheral Treg cell levels in chronic HBV compared to healthy individuals and self-403 
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limited HBV infection, others did not, similar to results in HCV infection[77-82]. This is 404 
complicated by different methods to define the Treg populations, which have evolved over 405 
time from simple staining of CD25 antigen to increasingly more complex and specific 406 
combinations of phenotypic markers, including FoxP3, PD-1 and CD127. Given their local 407 
mode of action, the presence and functionality of intrahepatic Treg cells should be most 408 
consequential, but almost all data is from the blood. It remains to be seen whether their main 409 
role is enabling chronic infection or rather protection from active liver disease in the context 410 
of long-term viremia. 411 
 412 
B cells and antibodies 413 
HBV-specific antibodies are clearly able to provide sterilizing immunity after vaccination. 414 
Clinically, different antibody profiles are important for the diagnosis and characterization of 415 
acute and chronic HBV infection. Much less is known about the relative contribution of B cells 416 
and HBV antibodies to viral control once infection has been established. B cells have been 417 
reported to display an activated phenotype and seem functionally intact, even at later stages 418 
of infection. We also recently demonstrated that blood gene signatures indicative of B cell 419 
responses were highly active during the immune active phase in chronic HBV patients, using 420 
a systems biology approach [12]. HBV antibodies target the surface, polymerase, core and x 421 
proteins of HBV, and appear ten to twelve weeks after infection. Detection of antibodies 422 
against HBsAg is the clinical correlate of protective immunity, but HBs antibodies likely 423 
contribute to control of viremia even in chronic infection where they are not detected by the 424 
standard antibody assays as they form immune complexes that prevent viral attachment and 425 
entry. In contrast, the core antibody (anti-HBc) is detectable in all stages of infection and 426 
considered not to mediate viral control, though the passive immunization of anti HBc/HBe 427 
does seem to prolong the incubation period in chimpanzees[83]. Overall a better 428 
characterization of how both B cells and antibody responses contribute to viral control during 429 
acute and chronic infection is urgently needed, as most likely a concerted effort by T cells 430 
and antibodies will offer the highest likelihood of effective HBV control. In this context it 431 
should also be noted that treatment with immunomodulatory drugs can lead to reactivation of 432 
controlled HBV infection[84]. The classic example is rituximab, a monoclonal antibody 433 
targeting CD20-expressing B cells, thus eliminating B cells and suppressing antibody 434 
production. It is not clear, however, whether the effect on antibodies is the sole or main 435 
cause for HBV reactivation, as rituximab treatment also impacts CD4 T cells and potentially 436 
indirectly also CD8 T cell memory[84, 85]. A detailed characterization of virus-specific 437 
immune responses during treatment with such agents should reveal important insights into 438 
immunological changes that might lead to diminished HBV control. 439 
  440 
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Summary  441 
Despite numerous immunological studies performed in HBV infected patients several key 442 
questions remain unanswered. For decades, the lack of HBV models facilitating replication of 443 
human strains hampered scientific progress, and even patient data can be misleading due to 444 
the huge variation among study cohorts of patients with chronic infection. Through careful 445 
patient selection and the use of modern biomedical techniques, like genomics and 446 
proteomics, researchers can now tackle basic questions regarding HBV 447 
immunopathogenesis. The aim should be to determine immune parameters associated with 448 
persistence, clearance and recurrence of HBV. Also, the mechanisms of recognition of viral 449 
antigens in chronic infections by hepatocytes in vivo remain unclear, with a particular need 450 
for ex vivo assays. Potential antiviral effector cells like Kupffer cells, natural killer cells and 451 
dendritic cell populations may be less functional during chronic infection, possibly leading to 452 
infrequent and exhausted HBV-specific T cells in adults. By the use of modern techniques, 453 
the function and phenotype of both peripheral and intrahepatic lymphocyte populations as 454 
well as hepatocytes can be determined, which may aid in the rational design of 455 
immunotherapeutic strategies.    456 
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Figure Legends 468 
 469 
Figure 1: Important questions concerning the clinical events and immunopathogenesis of 470 
chronic HBV infection remain unanswered. 471 
 472 
Figure 2: The persistence of HBV infections is determined by the complex interactions of 473 
multiple leukocytes.  474 
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